Quantitative analysis of cell surface antigen-antibody interaction using Gaussia princeps luciferase antibody fusion proteins

References

• Thillaivinayagalingam P, Gommeaux J, McLoughlin M, Collins D, Newcombe AR. Biopharmaceutical production: applications of surface plasmon resonance biosensors. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878:149-53; PMID:19762290; http://dx.doi.org/10.1016/j.jchromb.2009.08.040
   PubMed Web of Science ®Google Scholar
• Velazquez-Campoy A, Ohtaka H, Nezami A, Muzammil S, Freire E. Isothermal titration calorimetry. Curr Prot Cell Biol 2004; Chapter 17:Unit 17.8; PMID:18228446; http://dx.doi.org/10.1002/0471143030.cb1708s23
   PubMedGoogle Scholar
• Adumeau P, Sharma SK, Brent C, Zeglis BM. Site-specifically labeled immunoconjugates for molecular imaging–part 1: cysteine residues and glycans. Mol Imaging Biol 2016; 18:1-17; PMID:26754790; http://dx.doi.org/10.1007/s11307-015-0919-4
   PubMed Web of Science ®Google Scholar
• Subedi GP, Barb AW. The structural role of antibody N-glycosylation in receptor interactions. Structure (London, England : 1993) 2015; 23:1573-83; PMID:26211613; http://dx.doi.org/10.1016/j.str.2015.06.015
   PubMed Web of Science ®Google Scholar
• Nikic I, Lemke EA. Genetic code expansion enabled site-specific dual-color protein labeling: superresolution microscopy and beyond. Curr Opin Chem Biol 2015; 28:164-73; PMID:26302384; http://dx.doi.org/10.1016/j.cbpa.2015.07.021
   PubMedGoogle Scholar
• Cole NB. Site-specific protein labeling with SNAP-tags. Curr Prot Protein Sci 2013; 73: Unit 30.1; PMID:24510614; http://dx.doi.org/10.1002/0471140864.ps3001s73
   PubMedGoogle Scholar
• Haas AK, von Schwerin C, Matscheko D, Brinkmann U. Fluorescent Citrine-IgG fusion proteins produced in mammalian cells. MAbs 2010; 2:648-61; PMID:20724830; http://dx.doi.org/10.4161/mabs.2.6.13179
   PubMed Web of Science ®Google Scholar
• Tannous BA, Kim DE, Fernandez JL, Weissleder R, Breakefield XO. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther 2005; 11:435-43; PMID:15727940; http://dx.doi.org/10.1016/j.ymthe.2004.10.016
   PubMed Web of Science ®Google Scholar
• Fick A, Lang I, Schafer V, Seher A, Trebing J, Weisenberger D, Wajant H. Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14). J Biol Chem 2012; 287:484-95; PMID:22081603; http://dx.doi.org/10.1074/jbc.M111.287656
   PubMed Web of Science ®Google Scholar
• Lang I, Fick A, Schafer V, Giner T, Siegmund D, Wajant H. Signaling active CD95 receptor molecules trigger co-translocation of inactive CD95 molecules into lipid rafts. J Biol Chem 2012; 287:24026-42; PMID:22645131; http://dx.doi.org/10.1074/jbc.M111.328211
   PubMed Web of Science ®Google Scholar
• Salzmann S, Lang I, Rosenthal A, Schafer V, Weisenberger D, Carmona Arana JA, Trebing J, Siegmund D, Neumann M, Wajant H. TWEAK inhibits TRAF2-mediated CD40 signaling by destabilization of CD40 signaling complexes. J Immunol 2013; 191:2308-18; PMID:23918987; http://dx.doi.org/10.4049/jimmunol.1202899
   PubMed Web of Science ®Google Scholar
• El-Mesery M, Trebing J, Schafer V, Weisenberger D, Siegmund D, Wajant H. CD40-directed scFv-TRAIL fusion proteins induce CD40-restricted tumor cell death and activate dendritic cells. Cell Death Dis 2013; 4:e916; PMID:24232092; http://dx.doi.org/10.1038/cddis.2013.402
   PubMed Web of Science ®Google Scholar
• Trebing J, El-Mesery M, Schafer V, Weisenberger D, Siegmund D, Silence K, Wajant H. CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants. Cell Death Dis 2014; 5:e1035; PMID:24481449; http://dx.doi.org/10.1038/cddis.2013.555
   PubMed Web of Science ®Google Scholar
• Bittner S, Knoll G, Fullsack S, Kurz M, Wajant H, Ehrenschwender M. Soluble TL1A is sufficient for activation of death receptor 3. Febs j 2016; 283:323-36; PMID:26509650; http://dx.doi.org/10.1111/febs.13576
   PubMed Web of Science ®Google Scholar
• Lang I, Fullsack S, Wyzgol A, Fick A, Trebing J, Arana JA, Schäfer V, Weisenberger D, Wajant H. Binding studies of TNF receptor superfamily (TNFRSF) receptors on intact cells. J Biol Chem 2016; 291:5022-37; PMID:26721880; http://dx.doi.org/10.1074/jbc.M115.683946
   PubMed Web of Science ®Google Scholar
• Trebing J, Lang I, Chopra M, Salzmann S, Moshir M, Silence K, Riedel SS, Siegmund D, Beilhack A, Otto C, et al. A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo. MAbs 2014; 6:297-308; PMID:24135629; http://dx.doi.org/10.4161/mabs.26709
   PubMed Web of Science ®Google Scholar
• Wajant H. Principles of antibody-mediated TNF receptor activation. Cell Death Differ 2015; 22:1727-41; PMID:26292758; http://dx.doi.org/10.1038/cdd.2015.109
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 2012; 119:651-65; PMID:22053109; http://dx.doi.org/10.1182/blood-2011-04-325225
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 2013; 19:1035-43; PMID:23460534; http://dx.doi.org/10.1158/1078-0432.CCR-12-2064
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Ravetch JV. Fc-receptor interactions regulate both cytotoxic and immunomodulatory therapeutic antibody effector functions. Cancer Immunol Res 2015; 3:704-13; PMID:26138698; http://dx.doi.org/10.1158/2326-6066.CIR-15-0120
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Gordan S, Lux A. FcgammaR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends Immunol 2015; 36:325-36; PMID:25981969; http://dx.doi.org/10.1016/j.it.2015.04.005
   PubMed Web of Science ®Google Scholar
• Clark EA, Yip TC, Ledbetter JA, Yukawa H, Kikutani H, Kishimoto T, Ng MH. CDw40 and BLCa-specific monoclonal antibodies detect two distinct molecules which transmit progression signals to human B lymphocytes. Eur J Immunol 1988; 18:451-7; PMID:2451615; http://dx.doi.org/10.1002/eji.1830180320
   PubMed Web of Science ®Google Scholar
• Chodorge M, Zuger S, Stirnimann C, Briand C, Jermutus L, Grutter MG, Minter RR. A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency. Cell Death Differ 2012; 19:1187-95; PMID:22261618; http://dx.doi.org/10.1038/cdd.2011.208
   PubMed Web of Science ®Google Scholar
• Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, Huang F, Phan S, Gao S, Doern A, et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. MAbs 2009; 1:128-41; PMID:20061822; http://dx.doi.org/10.4161/mabs.1.2.7631
   PubMed Web of Science ®Google Scholar
• Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N, Tschopp J. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 1997; 7:831-6; PMID:9430228; http://dx.doi.org/10.1016/S1074-7613(00)80401-X
   PubMed Web of Science ®Google Scholar
• Wyzgol A, Muller N, Fick A, Munkel S, Grigoleit GU, Pfizenmaier K, Wajant H. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J Immunol 2009; 183:1851-61; PMID:19596991; http://dx.doi.org/10.4049/jimmunol.0802597
   PubMed Web of Science ®Google Scholar